| pubmed-article:19717790 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19717790 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:19717790 | lifeskim:mentions | umls-concept:C0948265 | lld:lifeskim |
| pubmed-article:19717790 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:19717790 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:19717790 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:19717790 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19717790 | pubmed:dateCreated | 2009-11-26 | lld:pubmed |
| pubmed-article:19717790 | pubmed:abstractText | Heme oxygenase (HO) and cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) participate in vascular protection, and recent studies suggest these two systems are functionally linked. We examined the consequences of HO deficiency on P450-derived EETs with regard to body weight, adiposity, insulin resistance, blood pressure, and vascular function in HO-2-null mice. The HO-2-null mice were obese, displayed insulin resistance, and had high blood pressure. HO-2 deficiency was associated with decreases in cyp2c expression, EET levels, HO-1 expression, and HO activity and with an increase in superoxide production and an impairment in the relaxing response to acetylcholine. In addition, HO-2-null mice exhibited increases in serum levels of tumor necrosis factor (TNF)-alpha and macrophage chemoattractant protein (MCP)-1 and a decrease in serum adiponectin levels. Treatment of HO-2-null mice with a dual-activity EET agonist/soluble epoxide hydrolase inhibitor increased renal and vascular EET levels and HO-1 expression, lowered blood pressure, prevented body weight gain, increased insulin sensitivity, reduced subcutaneous and visceral fat, and decreased serum TNF-alpha and MCP-1, while increasing adiponectin and restoring the relaxing responses to acetylcholine. The decrease in cyp2c expression and EETs levels in HO-2-null mice underscores the importance of the HO system in the regulation of epoxygenase levels and suggests that protection against obesity-induced cardiovascular complications requires interplay between these two systems. A deficiency in one of these protective systems may contribute to the adverse manifestations associated with the clinical progression of the metabolic syndrome. | lld:pubmed |
| pubmed-article:19717790 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19717790 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19717790 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19717790 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:19717790 | pubmed:issn | 1521-0103 | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:SchwartzmanMi... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:AbrahamNader... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:FalckJohn RJR | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:KimDong... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:InoueKazuyosh... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:GotlingerKath... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:VanellaLucaL | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:CanestraroMar... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:ManthatiVijay... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:KoduruSreeniv... | lld:pubmed |
| pubmed-article:19717790 | pubmed:author | pubmed-author:SodhiKomalK | lld:pubmed |
| pubmed-article:19717790 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19717790 | pubmed:volume | 331 | lld:pubmed |
| pubmed-article:19717790 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19717790 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19717790 | pubmed:pagination | 906-16 | lld:pubmed |
| pubmed-article:19717790 | pubmed:dateRevised | 2011-3-3 | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:meshHeading | pubmed-meshheading:19717790... | lld:pubmed |
| pubmed-article:19717790 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19717790 | pubmed:articleTitle | Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. | lld:pubmed |
| pubmed-article:19717790 | pubmed:affiliation | Department of Pharmacology New York Medical College, Valhalla, New York, USA. | lld:pubmed |
| pubmed-article:19717790 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19717790 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19717790 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19717790 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19717790 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19717790 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19717790 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19717790 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19717790 | lld:pubmed |
